<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Med</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Med</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2045-7634</journal-id><journal-id journal-id-type="publisher-id">CAM4</journal-id><journal-title-group><journal-title>Cancer Medicine</journal-title></journal-title-group><issn pub-type="epub">2045-7634</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5345627</article-id><article-id pub-id-type="doi">10.1002/cam4.1011</article-id><article-id pub-id-type="publisher-id">CAM41011</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Prevention</subject></subj-group></article-categories><title-group><article-title>Genetic variants in the plasminogen activator inhibitor&#8208;1 gene are associated with an increased risk of radiation pneumonitis in lung cancer patients</article-title></title-group><contrib-group><contrib id="cam41011-cr-0001" contrib-type="author"><name><surname>Liu</surname><given-names>Bo</given-names></name><xref ref-type="aff" rid="cam41011-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cam41011-cr-0002" contrib-type="author"><name><surname>Tang</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="cam41011-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cam41011-cr-0003" contrib-type="author"><name><surname>Yi</surname><given-names>Minxiao</given-names></name><xref ref-type="aff" rid="cam41011-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cam41011-cr-0004" contrib-type="author"><name><surname>Liu</surname><given-names>Qingxu</given-names></name><xref ref-type="aff" rid="cam41011-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cam41011-cr-0005" contrib-type="author"><name><surname>Xiong</surname><given-names>Huihua</given-names></name><xref ref-type="aff" rid="cam41011-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cam41011-cr-0006" contrib-type="author"><name><surname>Hu</surname><given-names>Guangyuan</given-names></name><xref ref-type="aff" rid="cam41011-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="cam41011-cr-0007" contrib-type="author" corresp="yes"><name><surname>Yuan</surname><given-names>Xianglin</given-names></name><address><email>yxl@medmail.com.cn</email></address><xref ref-type="aff" rid="cam41011-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="cam41011-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">Department of Oncology</named-content><institution>Tongji Hospital</institution><institution>Huazhong University of Science and Technology</institution><named-content content-type="city">Wuhan</named-content><named-content content-type="country-part">Hubei Province</named-content><country country="CN">China</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Xianglin Yuan, Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, 1095, Jiefang Road, Wuhan, China. Tel: +00862783663342; Fax:&#160;+00862783663342; E&#8208;mail: <email>yxl@medmail.com.cn</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>17</day><month>2</month><year>2017</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2017</year></pub-date><volume>6</volume><issue>3</issue><issue-id pub-id-type="doi">10.1002/cam4.2017.6.issue-3</issue-id><fpage>681</fpage><lpage>688</lpage><history><date date-type="received"><day>14</day><month>7</month><year>2016</year></date><date date-type="rev-recd"><day>14</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>18</day><month>12</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2017 Published by John Wiley & Sons Ltd. <copyright-statement>--><copyright-statement content-type="article-copyright">&#169; 2017 The Authors. <italic>Cancer Medicine</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:CAM4-6-681.pdf"/><abstract id="cam41011-abs-0001"><title>Abstract</title><p>Plasminogen activator inhibitor&#8208;1 (<styled-content style="fixed-case">PAI</styled-content>&#8208;1) plays a crucial role in the process of lung injury, although its association with radiation pneumonitis (<styled-content style="fixed-case">RP</styled-content>) is unclear. We hypothesized that genetic variants in <italic><styled-content style="fixed-case">PAI</styled-content>&#8208;1</italic> may influence the risk of <styled-content style="fixed-case">RP</styled-content>. In this study, 169 lung cancer patients were genotyped for six single&#8208;nucleotide polymorphisms in <italic><styled-content style="fixed-case">PAI</styled-content>&#8208;1</italic> using the Sequenom Mass<styled-content style="fixed-case">ARRAY</styled-content> system. The risk of <styled-content style="fixed-case">RP</styled-content> was evaluated by Cox proportional hazards analyses. The cumulative <styled-content style="fixed-case">RP</styled-content> probabilities by genotype were assessed using Kaplan&#8211;Meier analyses. Univariate and multivariate analyses revealed that <italic><styled-content style="fixed-case">PAI</styled-content>&#8208;1</italic>:rs7242 <styled-content style="fixed-case">GT</styled-content>/<styled-content style="fixed-case">GG</styled-content> was correlated with an increased occurrence of grade &#8805;3 <styled-content style="fixed-case">RP</styled-content> (crude hazard ratio&#160;=&#160;3.331; 95% confidence interval, 1.168&#8211;9.497; <italic>P&#160;</italic>=<italic>&#160;</italic>0.024). Our results indicated that <italic><styled-content style="fixed-case">PAI</styled-content>&#8208;1</italic>:rs7242 in the 3&#8242;&#8208;untranslated region of <italic><styled-content style="fixed-case">PAI</styled-content>&#8208;1</italic> can be a predictor of grade &#8805;3 <styled-content style="fixed-case">RP</styled-content> before radiotherapy.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="cam41011-kwd-0001">Lung cancer</kwd><kwd id="cam41011-kwd-0002"><styled-content style="fixed-case">PAI</styled-content>&#8208;1</kwd><kwd id="cam41011-kwd-0003">Radiation pneumonitis</kwd><kwd id="cam41011-kwd-0004">Radiotherapy</kwd><kwd id="cam41011-kwd-0005">Single&#8208;nucleotide polymorphism</kwd></kwd-group><funding-group><award-group><funding-source>National Natural Science Foundation of China</funding-source><award-id>81272492</award-id><award-id>81472921</award-id></award-group></funding-group><counts><fig-count count="1"/><table-count count="4"/><page-count count="8"/><word-count count="5926"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>cam41011</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>March 2017</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.0.8 mode:remove_FC converted:10.03.2017</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="cam41011-cit-1001">
<source>Cancer Medicine</source>
<year>2017</year>; <volume>6</volume>(<issue>3</issue>):<fpage>681</fpage>&#8211;<lpage>688</lpage>
</mixed-citation>
</p></notes></front><body><sec id="cam41011-sec-0001"><title>Introduction</title><p>Radiotherapy is a common modality for treating lung cancer <xref rid="cam41011-bib-0001" ref-type="ref">1</xref>. Radiation pneumonitis (RP) is a major side effect associated with radiotherapy which limits the therapeutic ratios of tumor treatment and reduces the living quality in patients who are irradiated for lung cancer. Approximately 16&#8211;30% of lung cancer patients experience severe RP after thoracic irradiation <xref rid="cam41011-bib-0002" ref-type="ref">2</xref>. Therefore, the exploration and application of RP biomarkers may help maximize efficacy and minimize adverse effects of radiotherapy. Previous studies have investigated and identified multiple therapeutic and patient&#8208;related factors that are associated with the incidence of RP including chemotherapy, smoking status, chronic lung disease, dosimetric parameters, and transforming growth factor (TGF)<italic>&#946;</italic> plasma concentrations <xref rid="cam41011-bib-0003" ref-type="ref">3</xref>, <xref rid="cam41011-bib-0004" ref-type="ref">4</xref>, <xref rid="cam41011-bib-0005" ref-type="ref">5</xref>, <xref rid="cam41011-bib-0006" ref-type="ref">6</xref>, <xref rid="cam41011-bib-0007" ref-type="ref">7</xref>, <xref rid="cam41011-bib-0008" ref-type="ref">8</xref>. However, only a small proportion of patients exposed to similar doses and volumes of irradiation develop RP, indicating that genetic factors perform a crucial role in the RP process. Our previous studies found that single&#8208;nucleotide polymorphisms (SNPs) in the TGF<italic>&#946;</italic> pathway were associated with RP risk <xref rid="cam41011-bib-0009" ref-type="ref">9</xref>, <xref rid="cam41011-bib-0010" ref-type="ref">10</xref>. Here, we expand upon our previous work by analyzing SNPs in plasminogen activator inhibitor&#8208;1 (<italic>PAI&#8208;1</italic>), an important target gene of TGF<italic>&#946;</italic> with RP risk <xref rid="cam41011-bib-0011" ref-type="ref">11</xref>.</p><p>PAI&#8208;1 is the main inhibitor of the plasmin system that blocks fibrinolysis and degradation of the extracellular matrix (ECM) <xref rid="cam41011-bib-0012" ref-type="ref">12</xref>. PAI&#8208;1 has been implicated in the progression of inflammatory and fibrotic lung diseases. For example, high levels of PAI&#8208;1 in lung edema fluid may affect mortality in acute lung injury <xref rid="cam41011-bib-0013" ref-type="ref">13</xref>. In mouse models, inhibiting PAI&#8208;1 expression by small interfering RNA or knockout of <italic>PAI&#8208;1</italic> attenuates bleomycin&#8208;induced lung fibrosis in comparison with wild&#8208;type mice <xref rid="cam41011-bib-0014" ref-type="ref">14</xref>, <xref rid="cam41011-bib-0015" ref-type="ref">15</xref>. Additionally, a recent study indicated that a truncated PAI&#8208;1 protein (rPAI&#8208;<sub>123</sub>) protects against radiation&#8208;induced lung injury in a murine model <xref rid="cam41011-bib-0016" ref-type="ref">16</xref>. Overall, these results implied that PAI&#8208;1 could be involved in the RP process.</p><p>Human <italic>PAI&#8208;1</italic> is located on chromosome 7q21.3&#8211;q22 and consists of eight introns and nine exons. SNPs in <italic>PAI&#8208;1</italic> may affect the transcriptional activation and plasma concentrations of PAI&#8208;1 <xref rid="cam41011-bib-0017" ref-type="ref">17</xref>. Previous studies demonstrated that <italic>PAI&#8208;1</italic> polymorphisms were associated with keloids, susceptibility to idiopathic interstitial pneumonia, myocardial infarction, and lung cancer prognosis <xref rid="cam41011-bib-0018" ref-type="ref">18</xref>, <xref rid="cam41011-bib-0019" ref-type="ref">19</xref>, <xref rid="cam41011-bib-0020" ref-type="ref">20</xref>, <xref rid="cam41011-bib-0021" ref-type="ref">21</xref>. However, no studies have examined how <italic>PAI&#8208;1</italic> polymorphisms influence the risk of RP. Here, we investigated the association of SNPs in <italic>PAI&#8208;1</italic> with RP risk in lung cancer patients treated with radiotherapy.</p></sec><sec id="cam41011-sec-0002"><title>Materials and Methods</title><sec id="cam41011-sec-0003"><title>Study populations</title><p>This prospective study (NCT02490319) included 169 lung cancer patients. All patients received radiotherapy between September 2008 and June 2014 at Tongji Hospital (Wuhan, China). The enrolled patients had an expected survival &gt; 6&#160;months, Karnofsky Performance Status &gt; 60, and received a radiation dose more than 45&#160;Gy. Exclusion criteria included respiratory infection or lung fibrosis, pulmonary emboli, cardiac disease, drug toxicity, and previous thoracic irradiation. The Tongji Hospital Review Board approved our study. All patients enrolled in the study signed written informed consents for DNA and clinical information.</p><p>All enrolled patients underwent radiotherapy with a 6&#8208;MV linear accelerator (Elekta, Stockholm, Sweden). The total radiation dose was reached by administering 1.5&#8211;2&#160;Gy per treatment. Dose&#8211;volume histogram data were shown in Table&#160;<xref rid="cam41011-sup-0001" ref-type="supplementary-material">S1</xref>. Seventy&#8208;nine patients received intensity&#8208;modulated radiation therapy. One hundred sixty patients received induction chemotherapy followed by radiation or concurrent chemotherapy and radiation, with 32.9% receiving a gemcitabine/cisplatin regimen, 19% a CPT&#8208;11/cisplatin regimen, 19.6% a docetaxel/cisplatin regimen, and 15.8% an etoposide/cisplatin regimen. We used a three&#8208;dimensional planning system (Pinnacle software, version 9.2; Philips Healthcare, Cleveland, OH) to delineate critical normal organs and target volumes.</p><p>Details of the follow&#8208;up schedule and the RP scoring criteria have been described previously <xref rid="cam41011-bib-0010" ref-type="ref">10</xref>. Briefly, RP was diagnosed by two radiation oncologists after reviewing chest X&#8208;ray or computed tomography scans, pulmonary function tests, and clinical information, including symptoms, at each follow&#8208;up visit. The patients were followed during and 1&#160;month after therapy, then every 3&#160;months. RP was scored according to the Common Terminology Criteria for Adverse Events 4.0. Symptomatic RP interfering with daily activities, or a requirement for oxygen, were defined as grade 3.</p></sec><sec id="cam41011-sec-0004"><title>Genotyping methods</title><p>Genomic DNA from all patients was extracted from peripheral blood via a blood DNA Kit (K1820&#8208;01; Invitrogen, Carlsbad, CA). Based on the public HapMap SNP database and HaploView 4.2 software, we searched for SNPs in <italic>PAI&#8208;1</italic> that had minor allele frequencies greater than 10%, positioned within the 15&#8208;kb region or in its upstream or downstream regulatory regions. We found that all eligible SNPs could be captured with r<sup>2</sup> &gt; 0.8 by five tagged SNPs: rs2227631, rs2227667, rs2227672, rs2227692, and rs7242. Together with the well&#8208;studied functional SNP rs1799768 (or 4G5G) <xref rid="cam41011-bib-0020" ref-type="ref">20</xref>, six SNPs in <italic>PAI&#8208;1</italic> were selected (Table&#160;<xref rid="cam41011-tbl-0001" ref-type="table-wrap">1</xref>). The SNPs were genotyped by the Sequenom MassARRAY system (Agena Bioscience, San Diego, CA) as described previously <xref rid="cam41011-bib-0010" ref-type="ref">10</xref>.</p><table-wrap id="cam41011-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characteristics of six SNPs selected for analysis</p></caption><table-wrap-foot><fn id="cam41011-note-0002"><p>SNP, single&#8208;nucleotide polymorphisms; UTR, untranslated region.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="cam41011-sec-0005"><title>Statistical analyses</title><p>The time for developing grade &#8805;3 RP was the endpoint used for this analysis. Data from patients were censored if they did not develop grade &#8805;3 RP within 1 year. SPSS version 19.0 (IBM, Chicago, IL) was used for statistical analyses. The Cox proportional hazards model was applied to estimate hazard ratios with 95% confidence intervals of different genotypes. Multivariate Cox regression analysis was used to adjust other covariates. Kaplan&#8211;Meier analyses were used to evaluate influences of the genotypes on RP between groups by log&#8208;rank tests. <italic>P&#160;</italic>&lt;<italic>&#160;</italic>0.05 was considered statistically significant in all tests.</p></sec></sec><sec id="cam41011-sec-0006"><title>Results</title><sec id="cam41011-sec-0007"><title>Patient characteristics and association with RP</title><p>Table&#160;<xref rid="cam41011-tbl-0002" ref-type="table-wrap">2</xref> lists characteristics of the 169 (125 male and 44 female) lung cancer patients (114 non&#8208;small&#8208;cell lung carcinoma and 55 small&#8208;cell lung carcinoma). The median age of patients was 57&#160;years (28&#8211;78&#160;years). One hundred six (62.0%) of the patients were smokers. Among the 169 patients, 145 (85.8%) had stage III&#8211;IV disease, 160 (94.7%) were treated with chemotherapy, and 86 (50.9%) underwent surgery before radiotherapy.</p><table-wrap id="cam41011-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Patient characteristics (<italic>n</italic>&#160;=&#160;169)</p></caption><table-wrap-foot><fn id="cam41011-note-0003"><p>KPS, Karnofsky performance status; CRT, concurrent chemoradiation; IMRT, intensity&#8208;modulated radiation therapy; MLD, mean lung dose; V<sub>20</sub>, volume of normal lung receiving 20&#160;Gy or more radiation; COPD, chronic obstructive pulmonary disease.</p></fn><fn id="cam41011-note-0004"><p>Smoker is the person who has or had smoked for more than 6&#160;months, including former smoker and current smoker.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The median follow&#8208;up time in this study was 22&#160;months (6&#8211;52&#160;months). After treatment with radiotherapy, 32 patients (18.9%) had grade &#8805;3 RP (grades 3, 4, and 5 were found in 29, 1, and 2 patients, respectively). We evaluated the association between clinicopathologic characteristics and grade &#8805;3 RP risk. According to multivariate analysis, V<sub>5</sub> &#8805;48%, V<sub>10</sub> &#8805; 38%, V<sub>20</sub> &#8805; 24% and a mean lung dose (MLD) &#8805;15&#160;Gy were associated with increased grade &#8805; 3 RP risk (<italic>P&#160;</italic>=<italic>&#160;</italic>0.009, <italic>P&#160;</italic>=<italic>&#160;</italic>0.019, <italic>P&#160;</italic>=<italic>&#160;</italic>0.034, and <italic>P&#160;</italic>=<italic>&#160;</italic>0.014, respectively). None of the other clinicopathologic characteristics were associated with a risk of RP in this study (Table&#160;<xref rid="cam41011-sup-0001" ref-type="supplementary-material">S1</xref> and Table&#160;<xref rid="cam41011-tbl-0003" ref-type="table-wrap">3</xref>).</p><table-wrap id="cam41011-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Association between patient characteristics and grade &#8805;3 RP</p></caption><table-wrap-foot><fn id="cam41011-note-0005"><p>Multivariate analyses were adjusted for sex, age, smoking, surgery, chemotherapy, and V<sub>20</sub>.</p></fn><fn id="cam41011-note-0006"><p>HR, hazard ratio; KPS, Karnofsky performance status; RT, radiotherapy; CRT, concurrent chemoradiation; IMRT, intensity&#8208;modulated radiation therapy; MLD, mean lung dose; V<sub>20</sub>, volume of normal lung receiving 20&#160;Gy or more radiation; COPD, chronic obstructive pulmonary disease.</p></fn><fn id="cam41011-note-0007"><p>MLD and V<sub>20</sub> were not used together in multivariate analyses.</p></fn><fn id="cam41011-note-0051"><p>
<italic>P</italic> &lt; 0.05 are presented in bold.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="cam41011-sec-0008"><title>RP and <italic>PAI&#8208;1</italic> polymorphisms</title><p>The associations between genetic polymorphisms and the risk of grade &#8805;3 are shown in Table&#160;<xref rid="cam41011-tbl-0004" ref-type="table-wrap">4</xref> using the Cox proportional hazards model. A significant association was found between rs7242 and the risk of grade &#8805;3 RP. Compared with the rs7242 TT genotype, the GT/GG genotypes had increased hazards of grade &#8805;3 RP (<italic>P&#160;=&#160;</italic>0.024). We found a similar result after multivariate analyses with adjustment for potential confounding factors of RP. The RP&#8208;free survival for grade &#8805;3 RP, according to rs7242 is plotted in Figure&#160;<xref rid="cam41011-fig-0001" ref-type="fig">1</xref>A. Development of grade &#8805;3 RP was prolonged in the rs7242 GG/GT genotypes, while no associations with grade &#8805;3 RP were found for the other SNPs.</p><table-wrap id="cam41011-tbl-0004" xml:lang="en" orientation="portrait" position="float"><label>Table 4</label><caption><p>Association between <italic>PAI&#8208;1</italic> genotypes and grade &#8805;3 RP</p></caption><table-wrap-foot><fn id="cam41011-note-0008"><p>Multiple analyses in this table were adjusted for sex, age, smoking, surgery, chemotherapy, and V<sub>20</sub>.</p></fn><fn id="cam41011-note-0009"><p>PAI&#8208;1, Plasminogen activator inhibitor&#8208;1; HR, hazard ratio.</p></fn><fn id="cam41011-note-0052"><p>
<italic>P</italic> &lt; 0.05 are presented in bold.</p></fn><fn id="cam41011-note-0010"><p>
<italic>NC</italic> not calculated.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder></permissions></table-wrap><fig fig-type="Figure" xml:lang="en" id="cam41011-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Kaplan&#8211;Meier estimates RP&#8208;free survival (RP &#8805; grade 3) as a function of time from the start of radiation therapy by genotypes. (A) rs7242; (B) rs7242 and V20; (C) rs7242 and <styled-content style="fixed-case">MLD</styled-content>. The rs7242 <styled-content style="fixed-case">GT</styled-content>/<styled-content style="fixed-case">GG</styled-content> genotypes was associated with a significantly higher risk of <styled-content style="fixed-case">RP</styled-content> as compared with <styled-content style="fixed-case">TT</styled-content> genotype (<italic>P&#160;</italic>=<italic>&#160;</italic>0.017). Patients with <styled-content style="fixed-case">GT</styled-content>/<styled-content style="fixed-case">GG</styled-content> genotype of rs7242 and V20&#160;&#8805;&#160;24% or <styled-content style="fixed-case">MLD</styled-content> &#8805; 15&#160;Gy had the highest grade &#8805;3 <styled-content style="fixed-case">RP</styled-content> risk compared with other groups.</p></caption><graphic id="nlm-graphic-3" xlink:href="CAM4-6-681-g001"/></fig></sec><sec id="cam41011-sec-0009"><title>
<italic>PAI&#8208;1:rs7242</italic> and dosimetric factors</title><p>The cumulative probability of grade &#8805;3 RP on the basis of genotype and V<sub>20</sub> as a function of time is shown in Figure&#160;<xref rid="cam41011-fig-0001" ref-type="fig">1</xref>B. The incidence of RP in patients receiving V<sub>20</sub>&#160;&#8805;&#160;24% and GT/GG genotypes in rs7242 were higher than patients who received V<sub>20</sub>&#160;&#8805;&#160;24% with the TT genotype in rs7242 (<italic>P&#160;</italic>=<italic>&#160;</italic>0.013). We also analyzed the cumulative RP incidence on the basis of MLD and genotypes as a function of time (Fig.&#160;<xref rid="cam41011-fig-0001" ref-type="fig">1</xref>C). Patients with a MLD&#160;&#8805;&#160;15&#160;Gy and GT/GG genotypes in rs7242 displayed a higher RP hazard than patients with the TT genotype and a MLD&#160;&#8805;&#160;15&#160;Gy (<italic>P&#160;</italic>=<italic>&#160;</italic>0.010). However, we did not observe this difference in patients who received V<sub>20</sub>&#160;&lt;&#160;24% or a MLD&#160;&lt;&#160;15.0&#160;Gy. These results suggest the independent role of rs7242 genotypes in grade &#8805;3 RP.</p></sec></sec><sec id="cam41011-sec-0010"><title>Discussion</title><p>This study examined whether genetic polymorphisms in <italic>PAI&#8208;1</italic> gene might be associated with an increased risk of RP in lung cancer patients receiving radiotherapy. We believe this is the first finding of an association between the presence of rs7242 in the 3&#8242;&#8208; untranslated region (UTR) of <italic>PAI&#8208;1</italic> and the risk of grade &#8805;3 RP. We found that patients with the rs7242 GG or GT genotypes exhibited an increased risk of RP following radiotherapy. Our results also indicated that the association between rs7242 and grade &#8805; 3 RP risk was independent of V<sub>20</sub> and MLD. Moreover, a group of patients (GT/GG genotypes in rs7242 and V<sub>20</sub> &#8805; 24% or MLD&#160;&#8805;&#160;15&#160;Gy) were found with the highest occurrence of grade &#8805;3 RP.</p><p>RP is a common complication following radiotherapy and is characterized by diffuse alveolar damage and subsequent fibrosis with excessive ECM deposition in the lung <xref rid="cam41011-bib-0022" ref-type="ref">22</xref>. PAI&#8208;1 is the main inhibitor of the plasmin system and has a crucial role in ECM accumulation by inhibiting fibrinolysis <xref rid="cam41011-bib-0012" ref-type="ref">12</xref>. Although little is known about the association between <italic>PAI&#8208;1</italic> polymorphisms and RP risk, several facts indicate that this association is biologically plausible. First, genetic variants in <italic>PAI&#8208;1</italic> influence the plasma levels of PAI&#8208;1 and are associated with other inflammatory or fibrotic diseases including keloids, myocardial infarction, and idiopathic interstitial pneumonia <xref rid="cam41011-bib-0018" ref-type="ref">18</xref>, <xref rid="cam41011-bib-0019" ref-type="ref">19</xref>, <xref rid="cam41011-bib-0020" ref-type="ref">20</xref>. Second, PAI&#8208;1 is implicated in the development of other radiation injury diseases. For example, there is a high level of PAI&#8208;1 in radiation&#8208;induced nephrosclerosis and the process of radiation enteritis <xref rid="cam41011-bib-0023" ref-type="ref">23</xref>, <xref rid="cam41011-bib-0024" ref-type="ref">24</xref>. <italic>PAI&#8208;1</italic> knockout mice have better survival and intestinal function compared with wild&#8208;type mice in radiation&#8208;induced intestinal injury <xref rid="cam41011-bib-0025" ref-type="ref">25</xref>. Finally, <italic>PAI&#8208;1</italic> is closely regulated by TGF&#8208;<italic>&#946;</italic>1, the cytokine that has a critical role in the RP process <xref rid="cam41011-bib-0022" ref-type="ref">22</xref>, <xref rid="cam41011-bib-0026" ref-type="ref">26</xref>. TGF&#8208;<italic>&#946;</italic>1 can regulate PAI&#8208;1 expression via SMAD&#8208;dependent and &#8208;independent pathways in numerous fibrotic diseases <xref rid="cam41011-bib-0011" ref-type="ref">11</xref>, <xref rid="cam41011-bib-0027" ref-type="ref">27</xref>, <xref rid="cam41011-bib-0028" ref-type="ref">28</xref>, <xref rid="cam41011-bib-0029" ref-type="ref">29</xref>, <xref rid="cam41011-bib-0030" ref-type="ref">30</xref>, <xref rid="cam41011-bib-0031" ref-type="ref">31</xref>. Moreover, TGF&#8208;<italic>&#946;</italic>1 increases PAI&#8208;1 plasma levels and promotes the epithelial&#8208;mesenchymal transition (EMT), while PAI&#8208;1 small interfering RNA prevents the TGF&#8208;<italic>&#946;</italic>1&#8208;induced EMT in mouse lung epithelial cells <xref rid="cam41011-bib-0012" ref-type="ref">12</xref>.</p><p>In this study, rs7242 was associated significantly with grade &#8805;3 RP. The rs7242 polymorphism is located in the 3&#8242;&#8208;UTR of <italic>PAI&#8208;1</italic> and is characterized by the substitution of a guanine with thymine. Studies have examined the relationships between this polymorphism and the risk of myocardial infarction, diffuse&#8208;type gastric cancer susceptibility, and primary ovarian insufficiency <xref rid="cam41011-bib-0019" ref-type="ref">19</xref>, <xref rid="cam41011-bib-0032" ref-type="ref">32</xref>, <xref rid="cam41011-bib-0033" ref-type="ref">33</xref>. In addition, previous studies found that haplotypes of this polymorphism may affect the plasma level of PAI&#8208;1 <xref rid="cam41011-bib-0032" ref-type="ref">32</xref>, <xref rid="cam41011-bib-0034" ref-type="ref">34</xref>. Other research reported that the rs7242 polymorphism may affect blood insulin concentrations <xref rid="cam41011-bib-0019" ref-type="ref">19</xref>. Because insulin levels play particular roles in lung diseases <xref rid="cam41011-bib-0035" ref-type="ref">35</xref>, rs7242 may also modulate the risk of RP by influencing insulin levels in cancer patients.</p><p>In summary, these facts suggest that the influence of rs7242 on RP is biologically plausible. However, in this study, we did not observe that other <italic>PAI&#8208;1</italic> polymorphisms affected the risk of RP. This included rs1799768 that can influence PAI&#8208;1 plasma levels and confer an increased risk of several inflammatory or fibrotic diseases such as myocardial infarction, asthma, nephropathy, and idiopathic interstitial pneumonia <xref rid="cam41011-bib-0020" ref-type="ref">20</xref>, <xref rid="cam41011-bib-0036" ref-type="ref">36</xref>, <xref rid="cam41011-bib-0037" ref-type="ref">37</xref>, <xref rid="cam41011-bib-0038" ref-type="ref">38</xref>. This finding may have been due to the different nature of the diseases and the small size of the study population.</p><p>Our study suggested that the rs7242 polymorphism can be used as a predictor of RP. In combination with our previous findings concerning RP susceptibility and SNPs in <italic>TGF&#946;1, ITGB6, PI3CA, AKT2</italic>, and <italic>MMP1</italic>
<xref rid="cam41011-bib-0009" ref-type="ref">9</xref>, <xref rid="cam41011-bib-0010" ref-type="ref">10</xref>, <xref rid="cam41011-bib-0039" ref-type="ref">39</xref>, <xref rid="cam41011-bib-0040" ref-type="ref">40</xref>, we can establish a more accurate model using these variants, enabling the prediction of RP by genotyping patients prior to radiotherapy. This would enable patients lacking RP susceptibility genotypes to receive appropriately elevated radiation doses to enhance tumor&#8208;related therapies.</p><p>In spite of these positive findings, some limitations of our study should be addressed. First, the population of this study was relatively small and thus the results need to be confirmed by further validation. Moreover, we were unable to explore the exact mechanism by which <italic>PAI&#8208;1</italic> polymorphisms led to RP in lung cancer patients. Finally, as the power in this exploratory study was limited, the <italic>P</italic> values in this study were not adjusted using Bonferroni corrections. Therefore, our findings are considered preliminary.</p><p>In conclusion, this study identified that rs7242 GT/GG genotypes located in the 3&#8242;&#8208;UTR of <italic>PAI&#8208;1</italic> were significantly associated with an increased risk of RP in lung cancer patients treated with radiotherapy. Our findings suggested that this polymorphism could be used to predict RP in lung cancer patients prior to initiating radiotherapy. However, further studies are essential to confirm our findings.</p></sec><sec id="cam41011-sec-0012"><title>Conflict of Interest</title><p>The authors have no conflict of interests.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="cam41011-sup-0001"><caption><p>
<bold>Table S1</bold>. Association between Dose&#8211;volume histogram data and grade &#8805; 3 RP.</p><p>
<bold>Table S2</bold>. Association between <italic>PAI&#8208;1</italic> genotypes and grade &#8805; 2 RP.</p></caption><media xlink:href="CAM4-6-681-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="cam41011-sec-0011"><title>Acknowledgments</title><p>This study was funded in part by the National Natural Science Foundation of China (grant numbers 81272492 and 81472921).</p></ack><ref-list content-type="cited-references" id="cam41011-bibl-0001"><title>References</title><ref id="cam41011-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="cam41011-cit-0001">
<string-name>
<surname>Killock</surname>, <given-names>D.</given-names>
</string-name>
<year>2014</year>
<article-title>Lung cancer: thoracic radiotherapy improves survival in small&#8208;cell lung cancer</article-title>. <source>Nat. Rev. Clin. Oncol.</source>
<volume>11</volume>:<fpage>623</fpage>.</mixed-citation></ref><ref id="cam41011-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="cam41011-cit-0002">
<string-name>
<surname>Kong</surname>, <given-names>F. M.</given-names>
</string-name>, and <string-name>
<given-names>S.</given-names>
<surname>Wang</surname>
</string-name>. <year>2015</year>
<article-title>Nondosimetric risk factors for radiation&#8208;induced lung toxicity</article-title>. <source>Semin. Radiat. Oncol.</source>
<volume>25</volume>:<fpage>100</fpage>&#8211;<lpage>109</lpage>.<pub-id pub-id-type="pmid">25771414</pub-id></mixed-citation></ref><ref id="cam41011-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="cam41011-cit-0003">
<string-name>
<surname>Palma</surname>, <given-names>D. A.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Senan</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Tsujino</surname>
</string-name>, <string-name>
<given-names>R. B.</given-names>
<surname>Barriger</surname>
</string-name>, <string-name>
<given-names>R.</given-names>&#160;<surname>Rengan</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Moreno</surname>
</string-name>, et&#160;al. <year>2013</year>
<article-title>Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta&#8208;analysis.Int</article-title>. <source>J. Radiat. Oncol. Biol. Phys.</source>
<volume>85</volume>:<fpage>444</fpage>&#8211;<lpage>450</lpage>.</mixed-citation></ref><ref id="cam41011-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="cam41011-cit-0004">
<string-name>
<surname>Stenmark</surname>, <given-names>M. H.</given-names>
</string-name>, <string-name>
<given-names>X. W.</given-names>
<surname>Cai</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Shedden</surname>
</string-name>, <string-name>
<given-names>J. A.</given-names>
<surname>Hayman</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Yuan</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Ritter</surname>
</string-name>, et&#160;al. <year>2012</year>
<article-title>Combining physical and biologic parameters to predict radiation&#8208;induced lung toxicity in patients with non&#8208;small&#8208;cell lung cancer treated with definitive radiation therapy</article-title>. <source>Int. J. Radiat. Oncol. Biol. Phys.</source>
<volume>84</volume>:<fpage>e217</fpage>&#8211;<lpage>e222</lpage>.<pub-id pub-id-type="pmid">22935395</pub-id></mixed-citation></ref><ref id="cam41011-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="cam41011-cit-0005">
<string-name>
<surname>Asakura</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Hashimoto</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Zenda</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Harada</surname>
</string-name>, <string-name>
<given-names>K.</given-names>&#160;<surname>Hirakawa</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Mizumoto</surname>
</string-name>, et&#160;al. <year>2010</year>
<article-title>Analysis of dose&#8208;volume histogram parameters for radiation pneumonitis after definitive concurrent chemoradiotherapy for esophageal cancer</article-title>. <source>Radiother. Oncol.</source>
<volume>95</volume>:<fpage>240</fpage>&#8211;<lpage>244</lpage>.<pub-id pub-id-type="pmid">20223539</pub-id></mixed-citation></ref><ref id="cam41011-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="cam41011-cit-0006">
<string-name>
<surname>Zhang</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Ding</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Sun</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Yang</surname>
</string-name>, et&#160;al. <year>2014</year>
<article-title>Genetic variants in inducible nitric oxide synthase gene are associated with the risk of radiation&#8208;induced lung injury in lung cancer patients receiving definitive thoracic radiation</article-title>. <source>Radiother. Oncol.</source>
<volume>111</volume>:<fpage>194</fpage>&#8211;<lpage>198</lpage>.<pub-id pub-id-type="pmid">24746566</pub-id></mixed-citation></ref><ref id="cam41011-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="cam41011-cit-0007">
<string-name>
<surname>Palmer</surname>, <given-names>J. D.</given-names>
</string-name>, <string-name>
<given-names>N. G.</given-names>
<surname>Zaorsky</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Witek</surname>
</string-name>, and <string-name>
<given-names>B.</given-names>
<surname>Lu</surname>
</string-name>. <year>2014</year>
<article-title>Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer</article-title>. <source>J. Thorac. Dis.</source>
<volume>6</volume>:<fpage>387</fpage>&#8211;<lpage>398</lpage>.<pub-id pub-id-type="pmid">24688783</pub-id></mixed-citation></ref><ref id="cam41011-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="cam41011-cit-0008">
<string-name>
<surname>Anscher</surname>, <given-names>M. S.</given-names>
</string-name>, <string-name>
<given-names>F. M.</given-names>
<surname>Kong</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Andrews</surname>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Clough</surname>
</string-name>, <string-name>
<given-names>L.&#160;B.</given-names>
<surname>Marks</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Bentel</surname>
</string-name>, et&#160;al. <year>1998</year>
<article-title>Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis</article-title>. <source>Int. J. Radiat. Oncol. Biol. Phys.</source>
<volume>41</volume>:<fpage>1029</fpage>&#8211;<lpage>1035</lpage>.<pub-id pub-id-type="pmid">9719112</pub-id></mixed-citation></ref><ref id="cam41011-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="cam41011-cit-0009">
<string-name>
<surname>Yuan</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Liao</surname>
</string-name>, <string-name>
<given-names>Z.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>L. E.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>S. L.</given-names>
<surname>Tucker</surname>
</string-name>, <string-name>
<given-names>L.</given-names>&#160;<surname>Mao</surname>
</string-name>, et&#160;al. <year>2009</year>
<article-title>Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non&#8208;small&#8208;cell lung cancer treated with definitive radiotherapy.J</article-title>. <source>Clin. Oncol.</source>
<volume>27</volume>:<fpage>3370</fpage>&#8211;<lpage>3378</lpage>.</mixed-citation></ref><ref id="cam41011-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="cam41011-cit-0010">
<string-name>
<surname>Tang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Yang</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Zhou</surname>
</string-name>, et&#160;al. <year>2016</year>
<article-title>Genetic variants in PI3K/AKT pathway are associated with severe radiation pneumonitis in lung cancer patients treated with radiation therapy</article-title>. <source>Cancer Med</source>
<volume>5</volume>:<fpage>24</fpage>&#8211;<lpage>32</lpage>.<pub-id pub-id-type="pmid">26645682</pub-id></mixed-citation></ref><ref id="cam41011-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="cam41011-cit-0011">
<string-name>
<surname>Samarakoon</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<given-names>J. M.</given-names>
<surname>Overstreet</surname>
</string-name>, and <string-name>
<given-names>P. J.</given-names>
<surname>Higgins</surname>
</string-name>. <year>2013</year>
<article-title>TGF&#8208;beta signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities</article-title>. <source>Cell. Signal.</source>
<volume>25</volume>:<fpage>264</fpage>&#8211;<lpage>268</lpage>.<pub-id pub-id-type="pmid">23063463</pub-id></mixed-citation></ref><ref id="cam41011-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="cam41011-cit-0012">
<string-name>
<surname>Ghosh</surname>, <given-names>A. K.</given-names>
</string-name>, and <string-name>
<given-names>D. E.</given-names>
<surname>Vaughan</surname>
</string-name>. <year>2012</year>
<article-title>PAI&#8208;1 in tissue fibrosis.J</article-title>. <source>Cell. Physiol.</source>
<volume>227</volume>:<fpage>493</fpage>&#8211;<lpage>507</lpage>.</mixed-citation></ref><ref id="cam41011-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="cam41011-cit-0013">
<string-name>
<surname>Prabhakaran</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<given-names>L. B.</given-names>
<surname>Ware</surname>
</string-name>, <string-name>
<given-names>K. E.</given-names>
<surname>White</surname>
</string-name>, <string-name>
<given-names>M. T.</given-names>
<surname>Cross</surname>
</string-name>, <string-name>
<given-names>M. A.</given-names>
<surname>Matthay</surname>
</string-name>, and <string-name>
<given-names>M. A.</given-names>
<surname>Olman</surname>
</string-name>. <year>2003</year>
<article-title>Elevated levels of plasminogen activator inhibitor&#8208;1 in pulmonary edema fluid are associated with mortality in acute lung injury</article-title>. <source>Am. J. Physiol. Lung Cell. Mol. Physiol.</source>
<volume>285</volume>:<fpage>L20</fpage>&#8211;<lpage>L28</lpage>.<pub-id pub-id-type="pmid">12730079</pub-id></mixed-citation></ref><ref id="cam41011-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="cam41011-cit-0014">
<string-name>
<surname>Eitzman</surname>, <given-names>D. T.</given-names>
</string-name>, <string-name>
<given-names>R. D.</given-names>
<surname>McCoy</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Zheng</surname>
</string-name>, <string-name>
<given-names>W. P.</given-names>
<surname>Fay</surname>
</string-name>, <string-name>
<given-names>T.</given-names>&#160;<surname>Shen</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Ginsburg</surname>
</string-name>, et&#160;al. <year>1996</year>
<article-title>Bleomycin&#8208;induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor&#8208;1 gene.J</article-title>. <source>Clin. Invest.</source>
<volume>97</volume>:<fpage>232</fpage>&#8211;<lpage>237</lpage>.</mixed-citation></ref><ref id="cam41011-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="cam41011-cit-0015">
<string-name>
<surname>Senoo</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Hattori</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Tanimoto</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Furonaka</surname>
</string-name>, <string-name>
<given-names>N.</given-names>&#160;<surname>Ishikawa</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Fujitaka</surname>
</string-name>, et&#160;al. <year>2010</year>
<article-title>Suppression of plasminogen activator inhibitor&#8208;1 by RNA interference attenuates pulmonary fibrosis</article-title>. <source>Thorax</source>
<volume>65</volume>:<fpage>334</fpage>&#8211;<lpage>340</lpage>.<pub-id pub-id-type="pmid">20388759</pub-id></mixed-citation></ref><ref id="cam41011-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="cam41011-cit-0016">
<string-name>
<surname>Chung</surname>, <given-names>E. J.</given-names>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>McKay&#8208;Corkum</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Chung</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>White</surname>
</string-name>, <string-name>
<given-names>B. T.</given-names>
<surname>Scroggins</surname>
</string-name>, <string-name>
<given-names>J. B.</given-names>
<surname>Mitchell</surname>
</string-name>, et&#160;al. <year>2016</year>
<article-title>Truncated Plasminogen Activator Inhibitor&#8208;1 Protein Protects From&#160;Pulmonary Fibrosis Mediated by Irradiation in a Murine Model</article-title>. <source>Int. J. Radiat. Oncol. Biol. Phys.</source>
<volume>94</volume>:<fpage>1163</fpage>&#8211;<lpage>1172</lpage>.<pub-id pub-id-type="pmid">26883561</pub-id></mixed-citation></ref><ref id="cam41011-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="cam41011-cit-0017">
<string-name>
<surname>Diamanti&#8208;Kandarakis</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Palioniko</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Alexandraki</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Bergiele</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Koutsouba</surname>
</string-name>, and <string-name>
<given-names>M.</given-names>
<surname>Bartzis</surname>
</string-name>. <year>2004</year>
<article-title>The prevalence of 4G5G polymorphism of plasminogen activator inhibitor&#8208;1 (PAI&#8208;1) gene in polycystic ovarian syndrome and its association with plasma PAI&#8208;1 levels</article-title>. <source>Eur. J. Endocrinol.</source>
<volume>150</volume>:<fpage>793</fpage>&#8211;<lpage>798</lpage>.<pub-id pub-id-type="pmid">15191349</pub-id></mixed-citation></ref><ref id="cam41011-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="cam41011-cit-0018">
<string-name>
<surname>Wang</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Long</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Wang</surname>
</string-name>, and <string-name>
<given-names>Y.</given-names>
<surname>Sun</surname>
</string-name>. <year>2014</year>
<article-title>Association of the plasminogen activator inhibitor&#8208;1 (PAI&#8208;1) Gene &#8208;675 4G/5G and &#8208;844 A/G promoter polymorphism with risk of keloid in a Chinese Han population</article-title>. <source>Med. Sci. Monit.</source>
<volume>20</volume>:<fpage>2069</fpage>&#8211;<lpage>2073</lpage>.<pub-id pub-id-type="pmid">25350781</pub-id></mixed-citation></ref><ref id="cam41011-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="cam41011-cit-0019">
<string-name>
<surname>Morange</surname>, <given-names>P. E.</given-names>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Saut</surname>
</string-name>, <string-name>
<given-names>M. C.</given-names>
<surname>Alessi</surname>
</string-name>, <string-name>
<given-names>J. S.</given-names>
<surname>Yudkin</surname>
</string-name>, <string-name>
<given-names>M.</given-names>&#160;<surname>Margaglione</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Di Minno</surname>
</string-name>, et&#160;al. <year>2007</year>
<article-title>Association of plasminogen activator inhibitor (PAI)&#8208;1 (SERPINE1) SNPs with myocardial infarction, plasma PAI&#8208;1, and metabolic parameters: the HIFMECH study</article-title>. <source>Arterioscler. Thromb. Vasc. Biol.</source>
<volume>27</volume>:<fpage>2250</fpage>&#8211;<lpage>2257</lpage>.<pub-id pub-id-type="pmid">17656673</pub-id></mixed-citation></ref><ref id="cam41011-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="cam41011-cit-0020">
<string-name>
<surname>Kim</surname>, <given-names>K. K.</given-names>
</string-name>, <string-name>
<given-names>K. R.</given-names>
<surname>Flaherty</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Long</surname>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Hattori</surname>
</string-name>, <string-name>
<given-names>T. H.</given-names>
<surname>Sisson</surname>
</string-name>, <string-name>
<given-names>T. V.</given-names>
<surname>Colby</surname>
</string-name>, et&#160;al. <year>2003</year>
<article-title>A plasminogen activator inhibitor&#8208;1 promoter polymorphism and idiopathic interstitial pneumonia</article-title>. <source>Mol. Med.</source>
<volume>9</volume>:<fpage>52</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">12765340</pub-id></mixed-citation></ref><ref id="cam41011-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="cam41011-cit-0021">
<string-name>
<surname>Di Bernardo</surname>, <given-names>M. C.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Matakidou</surname>
</string-name>, <string-name>
<given-names>T.</given-names>
<surname>Eisen</surname>
</string-name>, and <string-name>
<given-names>R. S.</given-names>
<surname>Houlston</surname>
</string-name>. <year>2009</year>
<article-title>Plasminogen activator inhibitor variants PAI&#8208;1 A15T and PAI&#8208;2 S413C influence lung cancer prognosis</article-title>. <source>Lung Cancer</source>
<volume>65</volume>:<fpage>237</fpage>&#8211;<lpage>241</lpage>.<pub-id pub-id-type="pmid">19117638</pub-id></mixed-citation></ref><ref id="cam41011-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="cam41011-cit-0022">
<string-name>
<surname>Flechsig</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Dadrich</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Bickelhaupt</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Jenne</surname>
</string-name>, <string-name>
<given-names>K.</given-names>&#160;<surname>Hauser</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Timke</surname>
</string-name>, et&#160;al. <year>2012</year>
<article-title>LY2109761 attenuates radiation&#8208;induced pulmonary murine fibrosis via reversal of TGF&#8208;beta and BMP&#8208;associated proinflammatory and proangiogenic signals</article-title>. <source>Clin. Cancer Res.</source>
<volume>18</volume>:<fpage>3616</fpage>&#8211;<lpage>3627</lpage>.<pub-id pub-id-type="pmid">22547771</pub-id></mixed-citation></ref><ref id="cam41011-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="cam41011-cit-0023">
<string-name>
<surname>Brown</surname>, <given-names>N. J.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Nakamura</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Ma</surname>
</string-name>, <string-name>
<given-names>I.</given-names>
<surname>Nakamura</surname>
</string-name>, <string-name>
<given-names>E.</given-names>&#160;<surname>Donnert</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Freeman</surname>
</string-name>, et&#160;al. <year>2000</year>
<article-title>Aldosterone modulates plasminogen activator inhibitor&#8208;1 and glomerulosclerosis in vivo</article-title>. <source>Kidney Int.</source>
<volume>58</volume>:<fpage>1219</fpage>&#8211;<lpage>1227</lpage>.<pub-id pub-id-type="pmid">10972684</pub-id></mixed-citation></ref><ref id="cam41011-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="cam41011-cit-0024">
<string-name>
<surname>Vozenin&#8208;Brotons</surname>, <given-names>M. C.</given-names>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Milliat</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Linard</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Strup</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Francois</surname>
</string-name>, <string-name>
<given-names>J. C.</given-names>
<surname>Sabourin</surname>
</string-name>, et&#160;al. <year>2004</year>
<article-title>Gene expression profile in human late radiation enteritis obtained by high&#8208;density cDNA array hybridization</article-title>. <source>Radiat. Res.</source>
<volume>161</volume>:<fpage>299</fpage>&#8211;<lpage>311</lpage>.<pub-id pub-id-type="pmid">14982484</pub-id></mixed-citation></ref><ref id="cam41011-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="cam41011-cit-0025">
<string-name>
<surname>Abderrahmani</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Francois</surname>
</string-name>, <string-name>
<given-names>V.</given-names>
<surname>Buard</surname>
</string-name>, <string-name>
<given-names>M.</given-names>&#160;<surname>Benderitter</surname>
</string-name>, <string-name>
<given-names>J. C.</given-names>
<surname>Sabourin</surname>
</string-name>, <string-name>
<given-names>D. L.</given-names>
<surname>Crandall</surname>
</string-name>, et&#160;al. <year>2009</year>
<article-title>Effects of pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor&#8208;1 in radiation&#8208;induced intestinal injury</article-title>. <source>Int. J. Radiat. Oncol. Biol. Phys.</source>
<volume>74</volume>:<fpage>942</fpage>&#8211;<lpage>948</lpage>.<pub-id pub-id-type="pmid">19480973</pub-id></mixed-citation></ref><ref id="cam41011-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="cam41011-cit-0026">
<string-name>
<surname>Park</surname>, <given-names>J. H.</given-names>
</string-name>, <string-name>
<given-names>S. H.</given-names>
<surname>Ryu</surname>
</string-name>, <string-name>
<given-names>E. K.</given-names>
<surname>Choi</surname>
</string-name>, <string-name>
<given-names>S. D.</given-names>
<surname>Ahn</surname>
</string-name>, <string-name>
<given-names>E.</given-names>
<surname>Park</surname>
</string-name>, <string-name>
<given-names>K. C.</given-names>
<surname>Choi</surname>
</string-name>, et&#160;al. <year>2015</year>
<article-title>SKI2162, an inhibitor of the TGF&#8208;beta type I receptor (ALK5), inhibits radiation&#8208;induced fibrosis in mice</article-title>. <source>Oncotarget.</source>
<volume>6</volume>:<fpage>4171</fpage>&#8211;<lpage>4179</lpage>.<pub-id pub-id-type="pmid">25686821</pub-id></mixed-citation></ref><ref id="cam41011-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="cam41011-cit-0027">
<string-name>
<surname>Liu</surname>, <given-names>R. M.</given-names>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Choi</surname>
</string-name>, <string-name>
<given-names>J. H.</given-names>
<surname>Wu</surname>
</string-name>, <string-name>
<given-names>K. A.</given-names>
<surname>Gaston Pravia</surname>
</string-name>, <string-name>
<given-names>K.&#160;M.</given-names>
<surname>Lewis</surname>
</string-name>, <string-name>
<given-names>J. D.</given-names>
<surname>Brand</surname>
</string-name>, et&#160;al. <year>2010</year>
<article-title>Oxidative modification of nuclear mitogen&#8208;activated protein kinase phosphatase 1 is involved in transforming growth factor beta1&#8208;induced expression of plasminogen activator inhibitor 1 in fibroblasts.J</article-title>. <source>Biol. Chem.</source>
<volume>285</volume>:<fpage>16239</fpage>&#8211;<lpage>16247</lpage>.</mixed-citation></ref><ref id="cam41011-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="cam41011-cit-0028">
<string-name>
<surname>Liu</surname>, <given-names>R. M.</given-names>
</string-name>
<year>2008</year>
<article-title>Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis</article-title>. <source>Antioxid. Redox Signal.</source>
<volume>10</volume>:<fpage>303</fpage>&#8211;<lpage>319</lpage>.<pub-id pub-id-type="pmid">17979497</pub-id></mixed-citation></ref><ref id="cam41011-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="cam41011-cit-0029">
<string-name>
<surname>He</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<given-names>R.</given-names>
<surname>Tan</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Dai</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Wang</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Hao</surname>
</string-name>, et&#160;al. <year>2010</year>
<article-title>Plasminogen activator inhibitor&#8208;1 is a transcriptional target of the canonical pathway of Wnt/beta&#8208;catenin signaling.J</article-title>. <source>Biol. Chem.</source>
<volume>285</volume>:<fpage>24665</fpage>&#8211;<lpage>24675</lpage>.</mixed-citation></ref><ref id="cam41011-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="cam41011-cit-0030">
<string-name>
<surname>Das</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<given-names>N.</given-names>
<surname>Ghosh&#8208;Choudhury</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Venkatesan</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>L.</given-names>&#160;<surname>Mahimainathan</surname>
</string-name>, and <string-name>
<given-names>G. G.</given-names>
<surname>Choudhury</surname>
</string-name>. <year>2008</year>
<article-title>Akt kinase targets association of CBP with SMAD 3 to regulate TGFbeta&#8208;induced expression of plasminogen activator inhibitor&#8208;1.J</article-title>. <source>Cell. Physiol.</source>
<volume>214</volume>:<fpage>513</fpage>&#8211;<lpage>527</lpage>.</mixed-citation></ref><ref id="cam41011-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="cam41011-cit-0031">
<string-name>
<surname>Zirlik</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Ernst</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Leugers</surname>
</string-name>, <string-name>
<given-names>F.</given-names>
<surname>Willecke</surname>
</string-name>, <string-name>
<given-names>B. E.</given-names>
<surname>Sobel</surname>
</string-name>, <string-name>
<given-names>C.</given-names>
<surname>Bode</surname>
</string-name>, et&#160;al. <year>2009</year>
<article-title>Inhibition by fibrates of plasminogen activator inhibitor type&#8208;1 expression in human adipocytes and preadipocytes</article-title>. <source>Thromb. Haemost.</source>
<volume>101</volume>:<fpage>1060</fpage>&#8211;<lpage>1069</lpage>.<pub-id pub-id-type="pmid">19492148</pub-id></mixed-citation></ref><ref id="cam41011-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="cam41011-cit-0032">
<string-name>
<surname>Jeon</surname>, <given-names>Y. J.</given-names>
</string-name>, <string-name>
<given-names>Y. R.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>B. E.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>S. H.</given-names>
<surname>Cha</surname>
</string-name>, <string-name>
<given-names>M. J.</given-names>
<surname>Moon</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Oh</surname>
</string-name>, et&#160;al. <year>2014</year>
<article-title>Association of five common polymorphisms in the plasminogen activator inhibitor&#8208;1 gene with primary ovarian insufficiency</article-title>. <source>Fertil. Steril.</source>
<volume>101</volume>:<fpage>825</fpage>&#8211;<lpage>832</lpage>.<pub-id pub-id-type="pmid">24355042</pub-id></mixed-citation></ref><ref id="cam41011-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="cam41011-cit-0033">
<string-name>
<surname>Ju</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Lim</surname>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>S. M.</given-names>
<surname>Noh</surname>
</string-name>, <string-name>
<given-names>W. H.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>C.</given-names>&#160;<surname>Ihm</surname>
</string-name>, et&#160;al. <year>2010</year>
<article-title>SERPINE1 intron polymorphisms affecting gene expression are associated with diffuse&#8208;type&#160;gastric cancer susceptibility</article-title>. <source>Cancer</source>
<volume>116</volume>:<fpage>4248</fpage>&#8211;<lpage>4255</lpage>.<pub-id pub-id-type="pmid">20549826</pub-id></mixed-citation></ref><ref id="cam41011-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="cam41011-cit-0034">
<string-name>
<surname>Jeon</surname>, <given-names>Y. J.</given-names>
</string-name>, <string-name>
<given-names>Y. R.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>B. E.</given-names>
<surname>Lee</surname>
</string-name>, <string-name>
<given-names>Y. S.</given-names>
<surname>Choi</surname>
</string-name>, <string-name>
<given-names>J. H.</given-names>
<surname>Kim</surname>
</string-name>, <string-name>
<given-names>J. E.</given-names>
<surname>Shin</surname>
</string-name>, et&#160;al. <year>2013</year>
<article-title>Genetic association of five plasminogen activator inhibitor&#8208;1 (PAI&#8208;1) polymorphisms and idiopathic recurrent pregnancy loss in Korean women</article-title>. <source>Thromb. Haemost.</source>
<volume>110</volume>:<fpage>742</fpage>&#8211;<lpage>750</lpage>.<pub-id pub-id-type="pmid">23903286</pub-id></mixed-citation></ref><ref id="cam41011-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="cam41011-cit-0035">
<string-name>
<surname>Honiden</surname>, <given-names>S.</given-names>
</string-name>, and <string-name>
<given-names>M. N.</given-names>
<surname>Gong</surname>
</string-name>. <year>2009</year>
<article-title>Diabetes, insulin, and development of acute lung injury</article-title>. <source>Crit. Care Med.</source>
<volume>37</volume>:<fpage>2455</fpage>&#8211;<lpage>2464</lpage>.<pub-id pub-id-type="pmid">19531947</pub-id></mixed-citation></ref><ref id="cam41011-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="cam41011-cit-0036">
<string-name>
<surname>Onalan</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Balta</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Oto</surname>
</string-name>, <string-name>
<given-names>G.</given-names>
<surname>Kabakci</surname>
</string-name>, <string-name>
<given-names>L.</given-names>
<surname>Tokgozoglu</surname>
</string-name>, <string-name>
<given-names>K.</given-names>
<surname>Aytemir</surname>
</string-name>, et&#160;al. <year>2008</year>
<article-title>Plasminogen activator inhibitor&#8208;1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease.J</article-title>. <source>Thromb. Thrombolysis.</source>
<volume>26</volume>:<fpage>211</fpage>&#8211;<lpage>217</lpage>.</mixed-citation></ref><ref id="cam41011-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="cam41011-cit-0037">
<string-name>
<surname>Cho</surname>, <given-names>S. H.</given-names>
</string-name>, <string-name>
<given-names>I. P.</given-names>
<surname>Hall</surname>
</string-name>, <string-name>
<given-names>A.</given-names>
<surname>Wheatley</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Dewar</surname>
</string-name>, <string-name>
<given-names>D.</given-names>
<surname>Abraha</surname>
</string-name>, <string-name>
<given-names>J.</given-names>
<surname>Del Mundo</surname>
</string-name>, et&#160;al. <year>2001</year>
<article-title>Possible role of the 4G/5G polymorphism of the plasminogen activator inhibitor 1 gene in the development of asthma.J</article-title>. <source>Allergy Clin. Immunol.</source>
<volume>108</volume>:<fpage>212</fpage>&#8211;<lpage>214</lpage>.</mixed-citation></ref><ref id="cam41011-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="cam41011-cit-0038">
<string-name>
<surname>Wong</surname>, <given-names>T. Y.</given-names>
</string-name>, <string-name>
<given-names>P.</given-names>
<surname>Poon</surname>
</string-name>, <string-name>
<given-names>C. C.</given-names>
<surname>Szeto</surname>
</string-name>, <string-name>
<given-names>J. C.</given-names>
<surname>Chan</surname>
</string-name>, and <string-name>
<given-names>P.&#160;K.</given-names>&#160;<surname>Li</surname>
</string-name>. <year>2000</year>
<article-title>Association of plasminogen activator inhibitor&#8208;1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients</article-title>. <source>Kidney Int.</source>
<volume>57</volume>:<fpage>632</fpage>&#8211;<lpage>638</lpage>.<pub-id pub-id-type="pmid">10652041</pub-id></mixed-citation></ref><ref id="cam41011-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="cam41011-cit-0039">
<string-name>
<surname>Yi</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Tang</surname>
</string-name>, <string-name>
<given-names>B.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Li</surname>
</string-name>, <string-name>
<given-names>X.</given-names>
<surname>Zhou</surname>
</string-name>, <string-name>
<given-names>S.</given-names>
<surname>Yu</surname>
</string-name>, et&#160;al. <year>2016</year>
<article-title>Genetic variants in the ITGB6 gene is associated with the risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy</article-title>. <source>Tumour Biol.</source>
<volume>37</volume>:<fpage>3469</fpage>&#8211;<lpage>3477</lpage>.<pub-id pub-id-type="pmid">26449830</pub-id></mixed-citation></ref><ref id="cam41011-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="cam41011-cit-0040">
<string-name>
<surname>Liu</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<given-names>M.</given-names>
<surname>Yi</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Tang</surname>
</string-name>, <string-name>
<given-names>Q.</given-names>
<surname>Liu</surname>
</string-name>, <string-name>
<given-names>H.</given-names>
<surname>Qiu</surname>
</string-name>, <string-name>
<given-names>Y.</given-names>
<surname>Zou</surname>
</string-name>, et&#160;al. <year>2016</year>
<article-title>MMP&#8208;1 promoter polymorphism is associated with risk of radiation&#8208;induced lung injury in lung cancer patients treated with radiotherapy</article-title>. <source>Oncotarget</source>
<volume>7</volume>:<fpage>70175</fpage>&#8211;<lpage>70184</lpage>.<pub-id pub-id-type="pmid">27659527</pub-id></mixed-citation></ref></ref-list></back></article>